Ibrutinib treatment improves T cell number and function in CLL patients.

Abstract

BACKGROUND Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton's tyrosine kinase (BTK) and IL-2-inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies. METHODS Peripheral blood mononuclear cells from chronic lymphocytic leukemia… (More)
DOI: 10.1172/JCI89756

Topics

9 Figures and Tables

Cite this paper

@article{Long2017IbrutinibTI, title={Ibrutinib treatment improves T cell number and function in CLL patients.}, author={Meixiao Long and Kyle Beckwith and Priscilla Do and Bethany L Mundy and Amber J Gordon and Amy M. Lehman and Kami J. Maddocks and Carolyn M. Cheney and Jeffrey A. Jones and Joseph M. Flynn and Leslie A. Andritsos and Farrukh T Awan and Joseph A Fraietta and Carl H June and Marcela V Maus and Jennifer A. Woyach and Michael A. Caligiuri and Amy J. Johnson and Natarajan Muthusamy and John C. Byrd}, journal={The Journal of clinical investigation}, year={2017}, volume={127 8}, pages={3052-3064} }